Long-term drug treatment of unipolar depression

R. M A Hirschfeld

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Depression is characterized by a recurrent course in many patients, and as a potentially chronic illness. It therefore often requires a long-term treatment strategy. This article proposes pragmatic answers to the questions involved in devising such a strategy, using the available literature. Cessation of treatment immediately after the observation of a response is associated with a high relapse rate, especially within the following 4 months, and all patients should therefore be treated for at least 3-6 months after the acute response to secure a stable remission. Patients at risk of recurrence should be considered for maintenance therapy thereafter. Such patients include those with prior episodes of depression within the last 5 years, those with a particularly severe or chronic depressive episode, those with residual symptoms scoring HAMD > 8 and also those whose age at onset was <25 or <60 years. Those who need maintenance therapy are likely to need it for a number of years, or indefinitely. SSRIs are better tolerated than TCAs or MAOIs and display similar efficacy in acute, continuation and maintenance treatment. They are less likely to be fatally toxic if taken in overdosage. There is growing evidence to support the use of a full therapeutic dose of antidepressant in maintenance treatment.

Original languageEnglish (US)
Pages (from-to)211-217
Number of pages7
JournalInternational Clinical Psychopharmacology
Volume11
Issue number4
StatePublished - 1996

Fingerprint

Depressive Disorder
Pharmaceutical Preparations
Therapeutics
Depression
Recurrence
Withholding Treatment
Poisons
Age of Onset
Antidepressive Agents
Chronic Disease
Observation

Keywords

  • maintenance therapy
  • prophylaxis
  • recurrence
  • relapse
  • unipolar depression

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Long-term drug treatment of unipolar depression. / Hirschfeld, R. M A.

In: International Clinical Psychopharmacology, Vol. 11, No. 4, 1996, p. 211-217.

Research output: Contribution to journalArticle

Hirschfeld, R. M A. / Long-term drug treatment of unipolar depression. In: International Clinical Psychopharmacology. 1996 ; Vol. 11, No. 4. pp. 211-217.
@article{ef50f408f9da48ebaf664379da19efe7,
title = "Long-term drug treatment of unipolar depression",
abstract = "Depression is characterized by a recurrent course in many patients, and as a potentially chronic illness. It therefore often requires a long-term treatment strategy. This article proposes pragmatic answers to the questions involved in devising such a strategy, using the available literature. Cessation of treatment immediately after the observation of a response is associated with a high relapse rate, especially within the following 4 months, and all patients should therefore be treated for at least 3-6 months after the acute response to secure a stable remission. Patients at risk of recurrence should be considered for maintenance therapy thereafter. Such patients include those with prior episodes of depression within the last 5 years, those with a particularly severe or chronic depressive episode, those with residual symptoms scoring HAMD > 8 and also those whose age at onset was <25 or <60 years. Those who need maintenance therapy are likely to need it for a number of years, or indefinitely. SSRIs are better tolerated than TCAs or MAOIs and display similar efficacy in acute, continuation and maintenance treatment. They are less likely to be fatally toxic if taken in overdosage. There is growing evidence to support the use of a full therapeutic dose of antidepressant in maintenance treatment.",
keywords = "maintenance therapy, prophylaxis, recurrence, relapse, unipolar depression",
author = "Hirschfeld, {R. M A}",
year = "1996",
language = "English (US)",
volume = "11",
pages = "211--217",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Long-term drug treatment of unipolar depression

AU - Hirschfeld, R. M A

PY - 1996

Y1 - 1996

N2 - Depression is characterized by a recurrent course in many patients, and as a potentially chronic illness. It therefore often requires a long-term treatment strategy. This article proposes pragmatic answers to the questions involved in devising such a strategy, using the available literature. Cessation of treatment immediately after the observation of a response is associated with a high relapse rate, especially within the following 4 months, and all patients should therefore be treated for at least 3-6 months after the acute response to secure a stable remission. Patients at risk of recurrence should be considered for maintenance therapy thereafter. Such patients include those with prior episodes of depression within the last 5 years, those with a particularly severe or chronic depressive episode, those with residual symptoms scoring HAMD > 8 and also those whose age at onset was <25 or <60 years. Those who need maintenance therapy are likely to need it for a number of years, or indefinitely. SSRIs are better tolerated than TCAs or MAOIs and display similar efficacy in acute, continuation and maintenance treatment. They are less likely to be fatally toxic if taken in overdosage. There is growing evidence to support the use of a full therapeutic dose of antidepressant in maintenance treatment.

AB - Depression is characterized by a recurrent course in many patients, and as a potentially chronic illness. It therefore often requires a long-term treatment strategy. This article proposes pragmatic answers to the questions involved in devising such a strategy, using the available literature. Cessation of treatment immediately after the observation of a response is associated with a high relapse rate, especially within the following 4 months, and all patients should therefore be treated for at least 3-6 months after the acute response to secure a stable remission. Patients at risk of recurrence should be considered for maintenance therapy thereafter. Such patients include those with prior episodes of depression within the last 5 years, those with a particularly severe or chronic depressive episode, those with residual symptoms scoring HAMD > 8 and also those whose age at onset was <25 or <60 years. Those who need maintenance therapy are likely to need it for a number of years, or indefinitely. SSRIs are better tolerated than TCAs or MAOIs and display similar efficacy in acute, continuation and maintenance treatment. They are less likely to be fatally toxic if taken in overdosage. There is growing evidence to support the use of a full therapeutic dose of antidepressant in maintenance treatment.

KW - maintenance therapy

KW - prophylaxis

KW - recurrence

KW - relapse

KW - unipolar depression

UR - http://www.scopus.com/inward/record.url?scp=0030463806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030463806&partnerID=8YFLogxK

M3 - Article

C2 - 9031986

AN - SCOPUS:0030463806

VL - 11

SP - 211

EP - 217

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 4

ER -